The Manufacturers Life Insurance Company Invests $322,000 in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

The Manufacturers Life Insurance Company bought a new position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 13,764 shares of the company’s stock, valued at approximately $322,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in ELVN. Quest Partners LLC increased its position in shares of Enliven Therapeutics by 87.3% during the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after acquiring an additional 742 shares in the last quarter. EntryPoint Capital LLC bought a new stake in shares of Enliven Therapeutics during the first quarter worth about $167,000. Blackstone Inc. bought a new stake in shares of Enliven Therapeutics during the first quarter worth about $443,000. American Century Companies Inc. increased its position in shares of Enliven Therapeutics by 44.7% during the second quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock worth $646,000 after acquiring an additional 8,540 shares in the last quarter. Finally, Rhumbline Advisers increased its position in shares of Enliven Therapeutics by 29.9% during the second quarter. Rhumbline Advisers now owns 49,627 shares of the company’s stock worth $1,160,000 after acquiring an additional 11,420 shares in the last quarter. 95.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a research report on Tuesday, October 1st.

Insider Transactions at Enliven Therapeutics

In related news, CFO Benjamin Hohl sold 5,250 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $26.68, for a total value of $140,070.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, insider Joseph P. Lyssikatos sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $26.70, for a total transaction of $320,400.00. Following the sale, the insider now directly owns 1,093,035 shares in the company, valued at approximately $29,184,034.50. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Benjamin Hohl sold 5,250 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $26.68, for a total transaction of $140,070.00. The disclosure for this sale can be found here. Insiders sold a total of 180,409 shares of company stock worth $4,800,526 in the last quarter. Insiders own 29.20% of the company’s stock.

Enliven Therapeutics Stock Performance

Shares of ELVN stock opened at $28.02 on Friday. Enliven Therapeutics, Inc. has a 52-week low of $9.80 and a 52-week high of $28.62. The company has a 50-day simple moving average of $23.92 and a two-hundred day simple moving average of $22.57. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of -14.52 and a beta of 1.10.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.17. On average, sell-side analysts forecast that Enliven Therapeutics, Inc. will post -1.98 EPS for the current fiscal year.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.